AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

SELLAS Life Sciences Group, Inc. Director's Dealing 2011

Mar 29, 2011

33651_dirs_2011-03-29_19a4c5b6-6b8a-489f-b814-dc8b1aceaa4c.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: RXI PHARMACEUTICALS CORP (RXII)
CIK: 0001390478
Period of Report: 2011-03-25

Reporting Person: KRIEGSMAN STEVEN A (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2011-03-25	Stock Option	$1.18	A	100000	Acquired	2021-03-24	Common Stock (100000)	Direct
2011-03-25	Stock Option	$1.18	A	200000	Acquired	2021-03-24	Common Stock (200000)	Direct

Footnotes

F1: Granted pursuant to the RXi Pharmaceuticals Corporation 2007 Incentive Plan.

F2: Per share.

F3: The options will vest in equal quarterly installments of 25,000 on each of June 25, 2011, September 25, 2011, December 25, 2011 and March 25, 2012.